EHA 2022 | Choosing between inotuzumab ozogamicin and blinatumomab in patients with R/R ALL
Anita Rijneveld
• 20 Jun 2022
Anita Rijneveld, MD, Erasmus MC, Rotterdam, Netherlands, gives recommendations on the use of blinatumomab and inotuzumab ozogamicin in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). According to Dr Rijneveld, patients who have central nervous system (CNS) involvement or patients with high tumor burden and high white blood cell count should be treated with inotuzumab ozogamicin, whilst patients at high risk of veno-occlusive disease (VOD), patients undergoing a second transplant, or elderly and heavily pre-treated patients should receive blinatumomab. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research funding from Servier and Amgen
